It was found that individuals with PCSK9- LOF (loss of function) variants had lower levels of LDL-C; therefore, PCSK9 inhibition was proposed as a possible therapeutic approach to hypercholesterolemia. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.